Dear Representatives Matsui and Brady:

I write on behalf of the American Academy of Allergy, Asthma & Immunology (AAAAI) to express our enthusiastic support for the Continuing Access to In-Home IVIG Act (H.R. 7839).

Established in 1943, the AAAAI is a professional organization with more than 7,000 members in the United States, Canada and 72 other countries. This membership includes allergist/immunologists (AI), other medical specialists, allied health, and related healthcare professionals—all with a special interest in the research and treatment of patients with allergic and immunologic diseases.

Our members are involved in the treatment of individuals with primary immunodeficiency (PI) diseases—a group of more than 300 genetic or intrinsic disorders in which part of the body’s immune system is missing or does not function properly. Infusions of intravenous immunoglobulin (IVIG) replacement therapy provide antibody replacement for patients with PI diseases. Board certified allergists/immunologists (AI) are the medical specialty trained to treat this rare disease patient population.

We appreciate your longtime leadership to ensure Medicare beneficiaries with PI diseases have access to the Medicare Part B home infusion benefit. The program provides Medicare PI patients the choice to avoid the hospital when their immunity is at the lowest. It is especially important during the current public health emergency to ensure that our patients have continued access to their medically necessary therapies.

(more)
Again, thank you for your work to improve the quality of life for our patients who struggle with PI diseases. We stand ready to work with you to ensure that Medicare PI patients have continued access to treatment at all sites of care, including the home setting. Should you have any questions, please contact Sheila Heitzig, Director of Practice and Policy, at sheitzig@aaaai.org or (414) 272-6071.

Sincerely,

Mary Beth Fasano, MD, MSPH, FAAAAI
President
American Academy of Allergy, Asthma & Immunology